Adagio CEO Tillman Gerngross resigns; COO David Hering appointed interim CEO

Invivyd, Inc.

David Hering appointed interim CEO, effective immediately; will also remain Chief Operating Officer.
Board initiated a formal CEO search for a candidate with commercial-stage experience.
Outgoing CEO Tillman Gerngross co-founded company, raised over $800M, advanced ADG20 into global pivotal trials for COVID-19.
Hering previously led Pfizer's mRNA global franchise and was President of North America Vaccines.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Tillman U. Gerngross

Chief Executive Officer and President

IVVD · Invivyd, Inc.

Effective: 2022-02-23
Successor: David Hering
Filed: February 23, 2022, 6:59 PM ET

On February 23, 2022, Tillman U. Gerngross, Ph.D. resigned as Chief Executive Officer and President of Adagio Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company.

Appointed (interim)

David Hering

Interim Chief Executive Officer

IVVD · Invivyd, Inc.

Effective: 2022-02-23
Filed: February 23, 2022, 6:59 PM ET

Following Dr. Gerngross’s resignation, on February 23, 2022, the Board appointed David Hering to serve as Interim Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tillman U. Gerngross resigned as Chief Executive Officer and President at Invivyd, Inc..

Action: resigned
Role: Chief Executive Officer and President

Exact text from the filing

On February 23, 2022, Tillman U. Gerngross, Ph.D. resigned as Chief Executive Officer and President of Adagio Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David Hering was appointed as Interim Chief Executive Officer at Invivyd, Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

Following Dr. Gerngross’s resignation, on February 23, 2022, the Board appointed David Hering to serve as Interim Chief Executive Officer.

View on SEC.gov

Invivyd, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-050174

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.